News on lab-developed tests and emerging diagnostic technologies.
The firm won't have to pay off its unsecured convertible notes until 2026 to investors, including Patrick Soon-Shiong's Nant Capital.
DiaSorin said that the acquisition gives it access to Luminex's multiplexing technology, tests, and instruments and strengthens its MDx product portfolio.
Core revenues were up 10 percent organically, while COVID-19 testing contributed $535 million to revenues in Q1 2021.
Four newly published PCR variant assays could potentially help health officials surveil communities and triage patients.
The researchers found that the reliable sampling of rare circulating tumor DNA fragments served as the key challenge for developing liquid biopsy assays.
